Stocks | | | As we head into the final weeks of December 2019, traders and investors alike can’t help but wonder if December concludes with the traditional holiday melt-up rally or repeat a brutal melt-down like December 2018. There are many similarities with last year but also stark differences. We will l... Read the Full Story |
|
From Our PartnersHackers and cyberterrorists are attacking America. They broke into computers at Lockheed Martin and Boeing to steal blueprints for military aircraft. Another "Cyber 9/11" is imminent. And the Trump administration is pouring $80 billion into cyberdefense. I've pinpointed the #1 cyberdefense contractor to receive that windfall spending -- and deliver investors up to 700% profits. | | Details here. |
|
Stocks | | |
One of the most interesting components of trading is that each and every day there are new factors that directly influence the prices of securities in the market. That means that every morning at the opening bell, there are plenty of new opportunities that traders can take advantage of. Part of be... Read the Full Story |
|
Stocks | | |
Earnings Season Doldrums Doesn’t Mean No Reports Are Out
With another 6 or 7 weeks until the peak of the 4th quarter earnings cycle, the market is anxious for whatever news it can get about how the quarter is going. The earnings calendar is short on names this week but there are some, and t... Read the Full Story |
|
From Our PartnersIf you're happy with stocks yielding you 4% or 5% a year, you don't need this. But if you want to see how we built a portfolio that now pays us a 67% cash on cash return - with no leverage, options, or gimmicks. | | Then go here ASAP. |
|
Stocks | | | UnitedHealth Group (NYSE: UNH) has been one of the best performing healthcare stocks this month and shares are trading within 2% of their all-time highs. Having fallen more than 25% from the end of last year through this past September, not many would have guessed that the $265 billion healthcare pr... Read the Full Story |
|
Markets | | | The third-quarter reporting for Children's Place noted a “small top-line miss” for the third quarter, due to familiar bugaboos like unusually nice weather that was keeping people out of shopping malls Read the Full Story |
|
From Our PartnersHundreds of thousands of Americans have been hit by a wave of wealth. Over the past year, the U.S. has minted an average of 1,800 new millionaires a day. How did they do it? For the first time in history, two of these millionaire investors have joined forces to help you learn the secret moneymaking strategy of the wealthy and connected. | | Click here to watch their presentation. |
|
The Early Bird Stock Of The Day Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas. | | View Today's Stock Pick |
|
